Disorders of cognitive activity in patients with multiple sclerosis and hepatocerebral degeneration and its prevention
Annotation. Currently, there is an increase in dementias of various origins, which is largely due to the tendency of the aging population of the globe, with adverse environmental factors. Dementia also occurs at a young, working-aged, which makes them not only a medical but also a social problem. The incidence of Alzheimer's disease (AD) is so high that the WHO has declared the 21st century the century of the AD epidemic. The task of the work is to conduct a comprehensive clinical and laboratory examination of patients with multiple sclerosis (MS) and patients with Wilson's disease (WD) to study the problem of neurodegenerative diseases. The Mini-Mental Status Exam (MMSE) scale was used to screen for cognitive function and to study the level of intellectual performance of patients. To determine verbal memory, the method was used: “memorization of 10 words”, and to study the personality and emotional sphere, the method of Derogatis SCl-90-P was used. The sample of patients with MS was 111 people, and psycho diagnostic examination of patients with WD was performed in 33 patients. Various cognitive disorders are characteristic of MS patients. The level of general intellectual productivity is in the range from normative indicators to very pronounced systemic disorders of cognitive functions. With the age of patients and the duration of the disease, the severity of these disorders increases. A comprehensive clinical and laboratory study showed that the pathogenesis and stages of development of the dementia process in patients with WD and MS coincide with those in patients with Alzheimer’s disease and depends on three groups of factors: genetic predisposition, natural (biological) aging, and endogenous and exogenous pathogenic factors. on the brain. The study concluded that in patients with WD and MS in the pathogenetic process are always involved structures that ensure the functioning of cognitive functions of the brain, which leads to the development of their defects. For the treatment and prevention of these patients, a comprehensive, pathogenetically grounded, and personalized therapy should be prescribed.
2. Voloshina, N. P. (1997). Dementiruyuschie protsessyi golovnogo mozga [Dementiating processes of the brain]. Harkov: Osnova.
3. Zaharov, V. V. (2009). Diagnostika i lechenie umerennyih kognitivnyih narusheniy [Diagnosis and treatment of mild cognitive impairment]. Nevrologiya, neyropsihiatriya, psihosomatika – Neurology, neuropsychiatry, psychosomatics, 2, 14–19. https://doi.org/10.14412/2074-2711-2009-32
4. Kalashnikova, L. A. (2005). Nevrologicheskie aspektyi sosudistoy dementsii [Neurological aspects of vascular dementia]. V Z. A. Suslina (Red.). Ocherki angionevrologii [Essays on angioneurology]. Moskva: Atmosfera. Vzyato s https://www.neurology.ru/ocherki-angionevrologii
5. Котов, А. С. (2016). Сосудистая деменция. Журнал медицинский совет, 5, 39–41. https://doi.org/10.21518/2079-701X-2016-05-39-41
6. Medvedev, A. V. (1996). Patogenez sosudistoy dementsii [Pathogenesis of vascular dementia]. Jurnal nevropatologii i psihiatrii im. S. S. Korsakova – Journal of Neuropathology and Psychiatry named after S.S. Korsakov, 96 (5), 95–100.
7. Merkin, A. G., Komarov, A. N., Kajin, V. A., Fonarev, A. V., Savelev, D. V., Fedotov, D. D., … & Nikiforov, I. A. (2016). Dementsiya v obschey praktike (differentsialnaya otsenka i terapiya) [Dementia in general practice (differential assessment and therapy)]. Nervnyie bolezni – Nervous Diseases, 2, 18–23. Vzyato s https://cyberleninka.ru/article/n/kognitivnye-narusheniya-posle-insulta-1
8. Preobrajenskaya, I. S. (2017). Sovremennyie podhodyi k diagnostike i lecheniyu bolezni Altsgeymera [Modern approaches to the diagnosis and treatment of Alzheimer's disease]. Meditsinskiy Sovet – Medical advice, 10, 26–31. https://doi.org/10.21518/2079-701X-2017-10-26-31
9. Frolkis, V. V. (1995). Starenie i vozrastnaya patologiya [Aging and age-related pathology]. Jurnal AMN Ukrainyi – Journal of the Academy of Medical Sciences of Ukraine, 1, 15–25.
10. Alvarez, A. (2018). BDNF v kachestve misheni lekarstvennogo preparata dlya lecheniya i profilaktiki kognitivnyih narusheniy posle insulta [BDNF as a drug target for the treatment and prevention of cognitive impairment after stroke]. Mejdunarodnyiy nevrologicheskiy jurnal – International Neurological Journal, 5 (99), 94–97.
11. Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, Ch-X., … & Grundke-Iqbal, I. (2005). Tau pathology in Alzheimer disease and other tauopathies. Biochimica et Biophysica Acta (BBA). 1739 (2–3), 198–210. doi: 10.1016/j.bbadis.2004.09.008
12. Lovenstone, S., & Gauthier, S. (2001). Management of dementia. London: Martin Dunitz.
13. Lulu Xie, Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., … & Nedergaard, M. (2013). Sleep drives metabolite clearance from the adult brain. Science, 342 (6156), 373-7. DOI: 10.1126/science.1241224
14. Masden, J. (1993). The use of SPECT for the diagnosis of dementia. New concepts in Vascular dementia. Barcelona: Espana.
15. Plosker, G. L., & Gauthier, S. (2009). Cerebrolysin: a review of its use in dementia. Drugs Aging, 26 (11), 893–915. doi: 10.2165/11203320-000000000-00000
16. Spector, A., Orrell, M., Davies, S., & Woods, B. (2000). Reality orientation for dementia: A Systematic Review of the Evidence of Effectiveness from Randomized Controlled Trials. The Gerontologist, 40, (2), 206–212. doi: 10.1093/geront/40.2.206
17. Van de Vorst, I. E., Vaartjes, I., Geerlings, M. I., Bots, M. L., & Koek, H. L. (2015). Prognosis of patients with dementia: results from a prospective nation-wide registry Linkage study in the Netherlands. BMJ. Open, 5 (10), e008897. doi: 10.1136/bmjopen-2015-008897
18. Weiner, M. W. (2005). Commentary on “Diagnosis of Alzheimer’s disease: Two decades of progress”. Central role of technology in the treatment and prevention of Alzheimer’s disease. Alzheimers Dement., 1 (2), 112–113. DOI: 10.1016/j.jalz.2005.09.006
This work is licensed under a Creative Commons Attribution 4.0 International License.